Leading the charge with a simple mantra “we do science well” is Bayer Pharmaceuticals’ president for the Americas, Sebastian Guth, a 45-year-old management PhD who took the position just a year ago after serving as the pharma unit’s global head of marketing. In the following conversation with In Vivo, Guth outlined his plans to execute two big product launches and multiple deals and new investments – all buttressed by a culture reset designed to open the organization to a new world of digital technology opportunities.
Bayer US Pharmaceuticals’ Sebastian Guth: Designs On A New Decade
Cancer, Cardio And Culture Are Top Of Mind Targets For Tomorrow’s Top Line Growth
Bayer’s ambitious campaign to reposition itself as a global leader in two complementary fields – health and nutrition – will face its toughest test in the US, with its highly litigious approach to product liability and a tendency to target pharmaceuticals as the source of the health system’s affordability and access problems.
